...
首页> 外文期刊>Acta Biochimica Polonica >Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer
【24h】

Plasma levels of VEGF-A, VEGF B, and VEGFR-1 and applicability of these parameters as tumor markers in diagnosis of breast cancer

机译:VEGF-A,VEGF B和VEGFR-1的血浆水平和这些参数的适用性作为肿瘤标志物在乳腺癌的诊断中

获取原文
获取原文并翻译 | 示例
           

摘要

The VEGF family members are important factors in promoting angiogenesis and lymphangiogenesis in malignant processes. The aim of this study was to investigate plasma concentrations of VEGF-A, VEGF-B and their soluble VEGFR-1 receptor and their diagnostic utility and potency as compared to CA 15-3 in breast cancer patients and in relation to the control group. The study included 120 breast cancer patients and 60 control patients. Plasma levels of tested parameters were determined with ELISA and CA 15-3 levels were determined with CMIA. Concentrations of all tested parameters in breast cancer patients showed statistically significant difference when compared to the control groups (benign breast tumor patients and/ or healthy women). VEGF-B showed the highest values of sensitivity (Sn) and predictive value of a negative test result (NPV) in total BC group (90% and 66.7%, respectively) and, more importantly, in stages I-II of BC (SE: 86.8%; 92.7%, NPV: 82.8%; 88.9%, respectively). Among all parameters tested, VEGF-A showed the highest specificity (Sf) (76.7%) and predictive value of a positive test result (PPV) (84.8%), yet they were lower than for CA 15-3. VEGF-A was also the best parameter that had statistically significant Area Under Curve (AUC) in stages I (0.678) and II (0.768). In the whole group of BC patients all parameters tested showed statistically significant AUC, but the maximum range was obtained for the combination of VEGF-A and CA 15-3 (0.817). The combined analysis of the studied parameters and CA 15-3 resulted in an increase in sensitivity and AUC values, which provides hope for developing a new panel of biomarkers that may be used in BC diagnosis in the future.
机译:VEGF家族成员是促进恶性过程中血管生成和淋巴管发生的重要因素。该研究的目的是研究VEGF-A,VEGF-B及其可溶性VEGFR-1受体的血浆浓度及其诊断效用和效力,与乳腺癌患者的CA 15-3相比和与对照组相关。该研究包括120例乳腺癌患者和60例对照患者。用ELISA测定测试参数的血浆水平,用CMIa测定Ca 15-3水平。与对照组(良性乳腺肿瘤患者和/或健康女性)相比,乳腺癌患者所有测试参数的浓度显示出统计学显着差异。 VEGF-B在BC组总组(分别为90%和66.7%)中显示出最高的敏感性(SN)和预测值,以及分别为90%和66.7%),更重要的是,在BC的阶段I-II(SE :86.8%; 92.7%,NPV:82.8%;分别为88.9%)。在测试的所有参数中,VEGF-A显示出最高的特异性(SF)(SF)(76.7%)和阳性测试结果(PPV)的预测值(PPV)(84.8%),但它们低于CA 15-3。 VEGF-A也是阶段I(0.678)和II(0.768)的曲线(AUC)下具有统计学意义的最佳参数。在整组BC患者中,所有测试的参数显示出统计学上显着的AUC,但是对于VEGF-A和CA 15-3的组合获得了最大范围(0.817)。研究参数和CA 15-3的综合分析导致灵敏度和AUC值的增加,这为开发可在未来BC诊断中使用的新型生物标志物的希望提供了希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号